Clinical Trial: A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07429045) titled 'A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body' on Feb. 18.

Brief Summary: The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.

Study Start Date: March 11, 2025

Study Type: INTERVENTIONAL

Condition: Overweight and Obesity

Intervention: DRUG: AMG 133

Participants will receive one dose of AMG 133 as a SC injection.

Recruitment Status: COMPLETED

Sponsor: Amgen

Published by HT Digital ...